Abstract
Silodosin and prostacure are two novel medications used in the treatment of men who have symptoms of an enlarged prostate gland, which is also known as benign enlargement prostate (benign prostatic hyperplasia BPH). The mutagenic and the effects of silodosin and prostacure on the fertility of human and animals have not been adequately studied. Therefore, the present study was performed to evaluate the effects of silodosin and prostacure on sperm-head abnormalities and genetic effects including micronuclei, DNA damage, chromosomal aberrations and embryonic toxicity in the male mice and embryos. Adult male mice were administrated orally with different dose levels as follow, the first and the second groups were administrated orally with two dose levels (8 and 16 mg/kg/day) once daily at approximately equal to IX and 2X the therapeutic dose of silodosin, the third and fourth groups were administrated orally with two dose levels (100 and 200 mg/kg/day) once daily approximately equal to 1X and 2X the therapeutic dose of prostacure and the fifth group was considered as a control group and administrated orally with distilled water. After 21 days of the treatments treated males were mated with untreated females, on day 18 of gestation the pregnant females and treated males were sacrificed and examined for sperm-abnormality, genetic and embryonic abnormalities. It was observed that silodosin at the two dose levels (8 and 16 mg/kg/day) induced slight increases in the frequencies of sperm-abnormalities, micronuclei formation, DNA damage chromosomal aberrations and embryonic toxicity compared with the control group but these increases were not statistically significant. On the other hand, in the males treated with the two dose levels (100 and 200 mg/kg/day) of prostacure there were decreases in the frequencies of sperm head abnormalities, micronuclei formation, DNA damage, chromosomal aberrations and embryonic toxicity including (absorbed and dead embryos) but these decreases were statistically significant only in the males treated with the double dose (200 mg/kg/day) compared with the controls. Thus, from the above results we can say that silodosin in the two dose levels was unable to induce statistically significant increases in the sperm-abnormalities, micronuclei formation, DNA damage, chromosomal aberrations and embryonic toxicity over the controls so; it is considered to be safe. While, prostacure induced significant decreases under the control level in the frequencies of sperm head abnormalities, micronuclei formation, DNA-damage, chromosomal aberrations and embryonic toxicity. So, prostacure is considered to be very safe to the males and their embryos and can improve their fertility.